文献类型：期刊文献

英文题名：Developing a medium combination to attain similar glycosylation profile to originator by DoE and cluster analysis method

作者：Xu, Jian[1];Shao, Zhihui[2];Wang, Zhanqing[3];Huang, Yingfeng[4];Zou, Xun[5];Shen, Yaling[1]

机构：[1]East China Univ Sci & Technol, Shanghai Collaborat Innovat Ctr Biomfg Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[2]Chinese Acad Sci, CAS Ctr Excellence Mol Plant Sci, Inst Plant Physiol & Ecol, CAS Key Lab Synthet Biol, Shanghai, Peoples R China;[3]Dragon Sail Pharmaceut, Proc Dev Dept, Shanghai, Peoples R China;[4]Dragonboat Biopharmaceut, R&D Labs, Shanghai, Peoples R China;[5]Shanghai Sanjin Biosci & Technol, Shanghai, Peoples R China

年份：2021

卷号：11

期号：1

外文期刊名：SCIENTIFIC REPORTS

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000636358400046)】；

语种：英文

摘要：Glycosylation is critical for monoclonal antibody production because of its impact on pharmacokinetics and pharmacodynamics. Modulation of glycan profile is frequently needed in biosimilar development. However, glycosylation profile is not a single value like that of cell culture titer, hence making it challenging for the Design of Experiment (DoE) methodology to be directly applied. In this study, a Her2-binding antibody was developed as a biosimilar to Herceptin. Cluster analysis was introduced to demonstrate the similarity of glycan profiles between the samples and the reference with specific value-distance. The glycosylation was subsequently optimized with the DoE method. Basal medium and feed medium were found to be the significant factors to the glycosylation pattern. Moreover, a combination of medium and feed strategy was developed to attain the most similar glycoprotein molecule to that of the originator biologic drug. This study may provide an additional option to evaluate multivariable factors and assess biosimilarity and/or comparability in monoclonal antibody production.